Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

被引：31

作者：

Coombs, Catherine C. ^{[1
]}

Sallman, David A. ^{[2
]}

Devlin, Sean M. ^{[3
]}

Dixit, Shweta

Mohanty, Abhinita ^{[5
]}

Knapp, Kristina ^{[4
]}

Al Ali, Najla H. ^{[2
]}

Lancet, Jeffrey E. ^{[2
]}

List, Alan F. ^{[2
]}

Komrokji, Rami S. ^{[2
]}

Padron, Eric ^{[2
]}

Arcila, Maria E. ^{[5
]}

Klimek, Virginia M. ^{[1
]}

van den Brink, Marcel R. M. ^{[6
]}

Tallman, Martin S. ^{[1
,7
]}

Levine, Ross L. ^{[1
,4
]}

Rampal, Raajit K. ^{[1
]}

Rapaport, Franck ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA

[7] Weill Cornell Med Coll, New York, NY USA

来源：

HAEMATOLOGICA | 2016年 / 101卷 / 11期

关键词：

OLDER PATIENTS; AZACITIDINE; PHENOTYPE; DNMT3A; IMPACT; IDH2; CARE; AML;

D O I：

10.3324/haematol.2016.148999

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E457 / E460

页数：4

共 50 条

[21] The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
Jiang, Xuejie
Wang, Zhixiang
Ding, Bingjie
Yin, Changxin
Zhong, Qingxiu
Carter, Bing Z.
Yu, Guopan
Jiang, Ling
Ye, Jieyu
Dai, Min
Zhang, Yu
Liang, Shuang
Zhao, Qingxia
Liu, Qifa
Meng, Fanyi
ONCOTARGET, 2015, 6 (32) : 33612 - 33622
[22] The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients
Jiang, Xuejie
Wang, Zhixiang
Yin, Changxin
Yu, Guopan
Ye, Jieyu
Zhang, Yu
Fan, Zhiping
Xu, Dan
Liu, Xiaoli
Feng, Ru
Xu, Bing
Sun, Jing
Liu, Qifa
Carter, Bing Z.
Meng, Fanyi
BLOOD, 2015, 126 (23)
[23] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
DiNardo, Courtney D.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
[24] Acute myeloid Leukemia Significance of hypomethylating Substances
Luebbert, Michael
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 156 - 156
[25] Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients
Gangat, Naseema
Karrar, Omer
Iftikhar, Moazah
Mccullough, Kristen
Johnson, Isla M.
Abdelmagid, Maymona
Abdallah, Mostafa
Al-Kali, Aref
Alkhateeb, Hassan B.
Begna, Kebede H.
Mangaonkar, Abhishek
Saliba, Antoine N.
Torghabeh, Mehrdad Hefazi
Litzow, Mark R.
Hogan, William
Shah, Mithun
Patnaik, Mrinal M.
Pardanani, Animesh
Badar, Talha
Murthy, Hemant
Foran, James
Palmer, Jeanne
Sproat, Lisa
Khera, Nandita
Yi, Cecilia Arana
Tefferi, Ayalew
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (02) : 193 - 202
[26] Comparable Survival of Treatment Naive TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy
Badar, Talha
Atallah, Ehab L.
Shallis, Rory M.
Patel, Anand Ashwin
Correia, Guilherme Sacchi De Camargo
Goldberg, Aaron D.
Saliba, Antoine
Bewersdorf, Jan Philipp
Duvall, Adam S.
Bradshaw, Danielle
Abaza, Yasmin
Murthy, Guru Subramanian Guru
Palmisiano, Neil
Kota, Vamsi K.
Litzow, Mark R.
BLOOD, 2023, 142
[27] Hypomethylating agent as first-line treatment for acute myeloid leukemia: Systematic review
Jhoputri, Caroline Fricilia
Tandokallo, Felicia
Kosayuz, Sherina
Atmaja, William Surya
Kurniawan, Andree
ANNALS OF ONCOLOGY, 2023, 34 : S1446 - S1446
[28] Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival
Jeurkar, Chetan
Wilde, Lindsay
Leiby, Benjamin E.
Banks, Joshua
Kasner, Margaret
Keiffer, Gina
Filicko-O'Hara, Joanne
Palmisiano, Neil
LEUKEMIA RESEARCH, 2021, 103
[29] Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Asghari, Hannah
Lee, Dasom
Deutsch, Yehuda E.
Chan, Onyee
Al Ali, Najla
Boisclair, Stephanie
Brahim, Amanda
Padron, Eric
Kuykendall, Andrew T.
List, Alan F.
Fernandez, Hugo F.
Lancet, Jeffrey E.
Sallman, David A.
Komrokji, Rami S.
Sweet, Kendra L.
Talati, Chetasi
BLOOD, 2019, 134
[30] Outcomes of Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Single Institution Analysis
Zimmer, Markie
Jacob, Brigid
Spica, Mikayla
Ghosh, Sunita
Dabak, Vrushali S.
BLOOD, 2024, 144 : 6040 - 6041

← 1 2 3 4 5 →